February / March #110 : Your Date With Data - by Tim Murphy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

You’ve Got Love!

Online Love 101

Make A Date!

The Real Deal

Legal Eye

HU Handbook

Editor's Letter


Hey, What’s Your Sign?

Glossed Over

What will they think of next?

Oh, No(bel) She Didn’t!


I Want My HIV TV!

Mama Mia

I Love My Heart

The Cheek of Them!

Booty Call

Your Date With Data

Warning Signs

STD Of The Month

The Antioxidant Buffet

Doin' the Hustle

Over The Wall

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

February / March 2005

Your Date With Data

by Tim Murphy

Tips from November’s ICAAC—the last of 2004’s big three HIV science and treatment confabs

Drugs we have
Early results in a two-nuke face-off show Emtriva and Viread—debuting elsewhere as Truvada—licking longtime nuke duo Combivir (AZT/3TC) in efficacy and side effects. Plus, over 11 months, the four-nuke combo of twice-daily Trizivir (AZT/3TC/ Ziagen) and once-daily Viread worked as well in first-time HAART takers, as the proven Combivir/Sustiva mix. Quad-ruple-nuke cocktails, anyone?

Drugs we need
HIVers with heavy resistance to protease inhibitors (PIs) did better if their combos included soon-to-be-released PI tipranavir (TPV) than any other PI. Those who paired TPV with Fuzeon  (T-20) did best—nearly half got their viral loads below 400. Moral of the story: If you’ve been around the protease block, save Fuzeon until you can snag some TPV (now in expanded access) to double-barrel it with.

Treatment tricks
One study tested 10 HAART-takers’ viral loads three times a week and found that brief “blips” of low detectable virus were common but not dangerous. Another discovered that HIVers who’d taken drug holidays from Sustiva or Viramune combos were more likely to show resistance when they went back on those non-nukes than those who took breaks from protease-inhibitor combos and later returned to them.

Coinfection treats
In HIVers coinfected with hepatitits C, pegylated interferon plus ribavirin achieved six-month response rates equal to those seen in folks with hep C alone—even if coinfectees had notoriously hard-to-treat hepatitis C genotype 1. Researchers credit the higher doses of riba-virin used in the study for the better-than-usual results. That’s OK—but we still want our up-and-coming hep C protease inhibitors!

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.